The trigonelline-induced reduction of Nrf2 signaling blocks proteasome activity, sensitizing tumor cells to apoptosis in vitro and reducing tumor growth in vivo when combined with etoposide [82]. The gene discussed is NFE2L2; the disease is neoplasm.